This suggests Her-2-positive breast cancer warrants finer stratification: Her-2 (3+) patients may benefit from dual-target or Tyrosine Kinase Inhibitors (TKIs) therapy, while Her-2 (2+)/FISH (+) patients could be treated based on Her-2/CEP17 ratios. This evidence concerns the gene ERBB2 and breast cancer.